Search
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[A244750] Glucarpidase is an enzyme that can rapidly hydrolyze methotrexate into its nontoxic metabolites. … This can lead to delayed renal clearance of methotrexate and elevated drug plasma levels, increasing the risk of methotrexate toxicity.
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago.
Polysilicone-15
go.drugbank.com/drugs/DB11271ApprovedWhen included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89].
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalof action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an … It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAlmasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However...
Propanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnSodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix). … It is considered generally recognized as safe (GRAS) food ingredient by FDA, where it acts as an antimicrobial agent for food preservation and flavoring agent.
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawnRemoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. … [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesSodium ferric gluconate complex
go.drugbank.com/drugs/DB09517ApprovedThe stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography. … Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia.